Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03905928 · ClinicalTrials.gov registry record · NA
Establishing the Effect of Flavor on the Addictive Potential of Electronic Cigarettes
A NA study, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT03905928: Completed NA study, sponsored by Milton S. Hershey Medical Center.
NCT03905928 is a NA study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 19 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03905928, a NA study, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
The current study aims to establish proof-of-concept that neural cue-reactivity can serve as an early, objective marker of electronic cigarette (ECIG) addictive potential. Further, this study will examine the effect of flavor and nicotine concentration on the addictive potential of ECIGs to aid research informing U.S. Food and Drug Administration (FDA) flavor regulations and smoking cessation.
Primary Outcome
Functional magnetic resonance imaging (fMRI) will be used to measure blood oxygen-level dependent (BOLD) signal in response to tobacco vs. strawberry-vanilla ECIG flavors at baseline. The means reported are the average percentage of BOLD signal change between the fMRI task odor conditions (tobacco vs. strawberry) identified using a whole-brain one-sample t-test with FSL software. Positive values indicate stronger BOLD signal during tobacco odor cues and negative values indicate stronger BOLD sig
Interventions
- OTHER Nicotine Containing ECIG with tobacco flavor
- OTHER Nicotine Containing ECIG with Strawberry Vanilla Flavor
- OTHER Placebo ECIG with Tobacco Flavor
- OTHER Placebo ECIG with Strawberry Vanilla Flavor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-11-04 |
| Est. Completion | 2024-04-30 |
| Phase | NA |
What the finished NCT03905928 record still lists
NCT03905928 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 4 interventions - of which Nicotine Containing ECIG with tobacco flavor is the first listed.
NCT03905928 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03905928 about?
NCT03905928 is a clinical study titled "Establishing the Effect of Flavor on the Addictive Potential of Electronic Cigarettes". The current study aims to establish proof-of-concept that neural cue-reactivity can serve as an early, objective marker of electronic cigarette (ECIG) addictive potential. Further, this study will examine the effect of flavor and nicotine concentration on the addictive potential of ECIGs to aid rese...
What is the current status of trial NCT03905928?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2019-11-04. Estimated completion is 2024-04-30.
What interventions are being tested in trial NCT03905928?
The interventions under investigation include: Nicotine Containing ECIG with tobacco flavor (OTHER), Nicotine Containing ECIG with Strawberry Vanilla Flavor (OTHER), Placebo ECIG with Tobacco Flavor (OTHER), Placebo ECIG with Strawberry Vanilla Flavor (OTHER).
Who is sponsoring clinical trial NCT03905928?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03905928's enrollment target sits among peer trials
19 1861st of 2000 higher than 138 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI